A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated With Human Rhinovirus Type 16

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated With Human Rhinovirus Type 16

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs CNTO 3157 (Primary)
  • Indications Asthma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 19 Jul 2017 Primary endpoint (The maximum percent decrease relative to baseline in the prebronchodilator forced expiratory volume in 1 second (FEV1) measurements (Part 2)) has not been met, according to results published in the Journal of Allergy and Clinical Immunology.
    • 19 Jul 2017 Results published in the Journal of Allergy and Clinical Immunology.
    • 11 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top